So the question I have to ask cgt, is this currently your fave...

So the question I have to ask cgt, is this currently your fave bio over ANP/BTA/PAB/IMU? Many know it's my fave and has been for a long time.

I agree with you re long-term contacts, strong patent position, large pharma interest with smaller competitors stumping up the cash as well.

Market cap wise, have to see the revenues hit the bottom line first IMO but def looks like deals are at the very late stages and it might be ok for me to say the 'hockey stick/snowball effect' may be coming into play!

Someone was asking about entry position.

If I were UNS, I would raise cash now with SP appreciation where it is. I pretty much inferred it on PAB (not to blow my own horn) because I knew management couldn't overlook it and it's prudent to do so before it falls back. However UNS is looking strong and if AS delivers a few more decent deals like Hikma before year end, then SP shouldn't be at these levels much longer IMO.

Looking forward to seeing BD on and maybe jessie/explorer as well.